SARRC’s Research Department is committed to identifying best practices for autism spectrum disorder (ASD) screening, diagnosis, and intervention, but we cannot do it alone. We look to individuals impacted by autism and their families to participate in our current research projects. Our research program utilizes rigorous research methods and is informed by the needs, preferences, and values of the community that we serve. Note: A stipend may be provided to cover the cost of time and travel.
We are currently enrolling adolescents aged 13-17 years with a diagnosis of autism spectrum disorder (ASD) to participate in a clinical trial evaluating the safety and efficacy of an investigational study drug compared to a placebo for treating irritability and agitation symptoms in adolescents with ASD.
In the IRIS research study, we are looking to find out whether an investigational drug might improve the symptoms of ASD that often make social interaction challenging. To qualify, participants must be 12 to 17 years of age; have a diagnosis of autism spectrum disorder (ASD) have a parent or guardian willing to assist during the study, and attend clinic visits.
SARRC is currently enrolling individuals between the ages of 2.5-5 years with ASD in the Leucovorin Study to assess the efficacy of an investigational natural treatment known as Levoleucovorin in enhancing language and social communication skills in children diagnosed with ASD. The 16-week clinical trial will help our team learn more about language and social communication in children with autism.
We are currently enrolling adults ages 18-45 years old who have a diagnosis of ASD to participate in a clinical trial designed to evaluate the safety and efficacy of a marijuana based oral solution compared to placebo in treating anxiety symptoms in adults with ASD.
Enrollment opens in May 2025.
SARRC is enrolling adults ages 21+ who use marijuana at least once a week to investigate the risks associated with marijuana use over 18 months. Study participation includes eight in-person visits, safety exams, logging marijuana use, and completing various assessments.
We are currently enrolling children ages 2-17 who can report an average of four nights/week of difficulties initiating sleep. This is a double-blind study looking into the effects of daily administration of an investigational medication on pediatric insomnia.
The Simons Foundation Autism Research Initiative is offering SPARK—an online, long-term study of genetics and autism. SPARK will collect and analyze genetic samples (saliva) from all participants to help autism researchers learn about genetic and non-genetic causes of autism. SPARK is open to all individuals with a professional diagnosis of autism, as well as their parents. Participation can take place either in your home via a mail-in kit or at SARRC.
We are currently enrolling individuals with autism, ages 12 to 65, who have a diagnosis of macrocephaly OR can provide documented head circumference data taken at any point after birth and before 24 months of age. This study aims to identify unique characteristics in individuals with autism through laboratory testing that potentially may lead to a more personalized approach to medicine.